Vecta Pharmaceuticals is developing an enhanced novel drug formulation for Symptomatic GERD

VCT111 is a unique, improved PPI (Proton Pump Inhibitor). VCT111 delivers superior efficacy and convenience over conventional PPI therapy. It offers daytime AND nighttime dosing flexibility and freedom from having to eat a meal to achieve therapeutic effect.

A dramatic improvement to existing PPI treatments

Nocturnal Relief

Daytime AND nighttime symptom relief

Superior PPI efficacy

 Clinical data shows enhanced effect of PPI therapy

Patient-centric

Allows flexible dosing, including bedtime administration

Phase-III ready
FDA Phase III

Short time timeframe to market with clear expedited roadmap

VCT111 is undergoing clinical trials to gain FDA approval